ACE	Angiotensin Converting Enzyme
ADA	American Diabetes Association
ADVANCE	Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation
ARBs	Angiotensin II Receptor Blockers
AWARD-7	A Study Comparing Dulaglutide with Insulin Glargine on Glycemic Control in Participants with Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
ASCVD	Atherosclerotic Cardiovascular Disease
BENEDICT	Bergamo Nephrologic Diabetic Complications
BP	Blood Pressure
CANVAS	Canagliflozin Cardiovascular Assessment
CKD	Chronic Kidney Disease
CI	Confidence Interval
CREDENCE	Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in participants with Diabetic Nephropathy
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats
DAPA-CKD	Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
DECLARE-TIMI	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
DN	Diabetic Nephropathy
DPP-4	Dipeptidyl Peptidase 4
DPP-4is	Dipeptidyl Peptidase 4 inhibitors
EASD	European Association for the Study of Diabetes
eGFR	estimated Glomerular Filtration Rate
ELIXA	Evaluation of Lixisenatide in Acute Coronary Syndrome
EMPA-KIDNEY	The Study of Heart and Kidney Protection with Empagliflozin, study of heart protection and kidneys with Empagliflozin
EMPA-REG	Empagliflozin cardiovascular outcome events in T2DM patients
ESRD	End-Stage Renal Disease
EXSCEL	Exenatide Study of Cardiovascular Event Lowering
FIDELIO-DKD	Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease
FIGARO-DKD	Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic kidney Disease
FLOWA	Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease
GFR	Glomerular Filtration Rate
GLP-1	Glucagon-Like Peptide-1
GLP-1 Ras	Glucagon-Like Peptide-1 Receptor Agonists
HbA1c	Hemoglobin A1c
HR	Hazard Ratio
KIDNEY	The Study of Heart and Kidney Protection with Empagliflozin
ICAM1	Intercellular Adhesion Molecule 1
LDL-C	Low-Density Lipoproteins Cholesterol
LEADER	Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation
MACE	Major Adverse Cardiovascular Events
MRA	Mineralocorticoid Receptor Antagonist
NHE3	Sodium Hydrogen Exchanger 3
NSAIDs	Nonsteroidal Anti-Inflammatory Drugs
PCSK9	ProproteinConvertase Subtilisin/Kexin type 9
PIONEER-6	Cardiovascular Safety of Oral Semaglutide in Subjects with Type 2 Diabetes
RAS	Renin-Angiotensin System
RASS	Renin-Angiotensin System Study
RCTs	Randomized Controlled Trials
REWIND	Researching Cardiovascular Events with a Weekly Incretin in Diabetes
ROADMAP	Randomized Olmesartan and Diabetes Microalbuminuria Prevention
ROS	Reactive Oxygen Species
RRT	Renal Replacement Therapy
SGLT-2is	Sodium Glucose Cotransporter 2 inhibitors
SUSTAIN-6	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Cardiovascular Outcome
T2DM	Type 2 Diabetes Mellitus
UACR	Urinary Albumin-To-Creatinine Ratio
VCAM1	Vascular Cell Adhesion Molecule 1
VLDL	Very Low-Density Lipoprotein